Last reviewed · How we verify
Fecal Microbiota Transplant; Vancomycin
At a glance
| Generic name | Fecal Microbiota Transplant; Vancomycin |
|---|---|
| Also known as | FMT, vancomycin |
| Sponsor | ProgenaBiome |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure (PHASE1)
- Intestinal Microbiome Transplant in ALS (PHASE1, PHASE2)
- Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders (PHASE2)
- PMT for MDRO Decolonization (PHASE2)
- Familial Fecal Microbiota Transplant for the Treatment of Subjects With Autism Spectrum Disorders (PHASE1)
- Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence (PHASE3)
- STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection (NA)
- Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fecal Microbiota Transplant; Vancomycin CI brief — competitive landscape report
- Fecal Microbiota Transplant; Vancomycin updates RSS · CI watch RSS
- ProgenaBiome portfolio CI